Details for Patent: RE49302
Which drugs does patent RE49302 protect, and when does it expire?
Patent RE49302 protects VRAYLAR and is included in one NDA.
Protection for VRAYLAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-seven patent family members in thirty-three countries.
Summary for Patent: RE49302
| Title: | Pharmaceutical formulations containing dopamine receptor ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Ranajoy Sarkar, Mahendra G. Dedhiya, Anil Chhettry | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Richter Gedeon Nyrt | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/384,264 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent RE49302 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent RE49302: Cariprazine Formulation Claims, Scope, Expiry and Generic RiskU.S. Patent RE49302 covers methods of treating schizophrenia, bipolar disorder, acute mania, and depression with low-dose solid oral cariprazine formulations. Its strongest protection is concentrated in two claim groups: pharmacokinetically defined formulations containing low-water-activity excipients, and dose-specific formulations containing pregelatinized starch. The patent does not claim cariprazine as a chemical compound. It is a formulation and method-of-treatment patent directed to the marketed Vraylar dosage range. What drug does U.S. Patent RE49302 protect?RE49302 protects cariprazine, also known by its chemical name trans-1-{4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl}-3,3-dimethylurea. The marketed product is cariprazine hydrochloride, sold in the United States as Vraylar by AbbVie.[1]
Cariprazine is an atypical antipsychotic with dopamine D3 and D2 receptor partial agonist activity. FDA-approved Vraylar indications include schizophrenia in adults, manic or mixed episodes associated with bipolar I disorder, depressive episodes associated with bipolar I disorder, and adjunctive treatment of major depressive disorder in adults.[1] What are the independent claims of RE49302?RE49302 contains two independent claims. Claim 1: pharmacokinetic and formulation-defined treatment methodClaim 1 requires all of the following:
The claim is cumulative. A product or method that satisfies only the dose and excipient limitations does not necessarily infringe claim 1 if it does not satisfy the pharmacokinetic, dissolution and pH limitations. Claim 11: dose and pregelatinized-starch methodClaim 11 is materially broader in one respect. It requires:
Unlike claim 1, claim 11 does not expressly require the claimed Cmax, AUC, Tmax, dissolution rate or pH range. Claims 12-15 narrow claim 11 to individual dose strengths. How do the dependent claims divide the patent scope?
The commercial significance lies in claims 11-15. They map directly onto the principal Vraylar capsule strengths and avoid several of claim 1's measurable performance limitations. What formulations are protected by RE49302?The patent protects solid oral formulations that use a low-water-activity excipient. The specified excipients are pregelatinized starch, mannitol and anhydrous calcium hydrogen phosphate. Pregelatinized starchPregelatinized starch is the most commercially important excipient under the claims because claims 11-15 expressly require it. A solid oral cariprazine product containing one of the four specified strengths and pregelatinized starch may fall within claims 11-15 even if its formulation does not exhibit the PK, pH or dissolution profile recited in claim 1. For an ANDA applicant, excipient substitution is a potential design-around route. That route is not automatically sufficient because:
Mannitol and anhydrous calcium hydrogen phosphateMannitol and anhydrous calcium hydrogen phosphate are expressly covered by claims 1 and 9-10. They are not expressly included in the narrower independent claim 11. A formulation using mannitol or anhydrous calcium hydrogen phosphate therefore presents a different risk profile from a pregelatinized-starch formulation. It may avoid claims 11-15 while still implicating claim 1 if the PK, dissolution and pH limitations are met. pH and dissolutionClaim 1 requires a formulation pH of approximately 9.0-12.0 and more than 80% dissolution within approximately 60 minutes after administration of the composition. These limitations create evidentiary issues:
A generic formulation can be outside claim 1 if it fails any one of those limitations. That does not resolve risk under claims 11-15. How strong is the patent estate for Vraylar and cariprazine?RE49302 is a targeted patent rather than a basic compound patent. Its strength depends on the formulation used by the generic applicant and on whether the claims are listed for the relevant Vraylar products in the FDA Orange Book. Strengths
Limitations
Overall, the patent is stronger against a formulation that copies the Vraylar excipient system and approved dose strengths than against a generic that uses a materially different excipient architecture. When does RE49302 lose exclusivity?The controlling patent term is the term of the original patent from which the reissue derives, subject to any applicable patent-term adjustment, terminal disclaimer or other term record.[2] A reissue does not ordinarily create a new patent term independent of the original patent. RE49302 is associated with the cariprazine formulation patent family and has been publicly identified in connection with Vraylar patent protection. The operative expiration date should be taken from the USPTO patent record and the current FDA Orange Book listing because the expiration calculation can depend on the original patent term, patent-term adjustment and any terminal disclaimer.[2,3]
The FDA approved Vraylar in 2015. The initial five-year NCE exclusivity period therefore did not remain the primary barrier after 2020. Current market protection is driven mainly by patents, including formulation and method-of-use patents, rather than by NCE exclusivity.[1,3] What is the Orange Book status of RE49302?The Orange Book is the controlling FDA source for patents submitted by the NDA holder and associated with approved products. A listed patent can require an ANDA applicant to submit a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable or not infringed.[3] RE49302 should be analyzed together with the complete Vraylar patent listing, not in isolation. The relevant questions are:
The claim language supplied for RE49302 indicates coverage directed to treatment of schizophrenia, bipolar disorder, acute mania and depression. That scope is broader than a single indication, but the enforceability of any particular use depends on the approved labeling and the listing data. Which companies are challenging Vraylar patents?A patent challenge requires a specific ANDA, Paragraph IV certification, district-court complaint or inter partes review record. The RE49302 claims alone do not establish that a particular company has filed a challenge. The principal potential challengers are generic manufacturers seeking approval for cariprazine capsules, including large ANDA sponsors and specialty generic companies. Their likely strategies are:
For RE49302 specifically, a Paragraph IV case would likely focus on written description, enablement, indefiniteness, obviousness, anticipation and infringement. The broadest practical defense would be a formulation that does not contain a listed excipient and does not satisfy the claim 1 performance limitations. What patent litigation affects cariprazine generic entry?Vraylar generic-entry litigation would typically arise under the Hatch-Waxman framework. After an ANDA applicant provides a Paragraph IV notice, the NDA holder may sue within 45 days. A timely suit can trigger a 30-month FDA approval stay, subject to statutory exceptions and court action.[4] The litigation risk is strongest when:
A generic applicant could reduce exposure through a non-infringing formulation, a section viii label carve-out, a Paragraph III certification, or an agreement resolving litigation before judgment. A settlement may include a deferred launch date, a license, an authorized-generic arrangement or restrictions on the scope of the launch. No settlement terms should be inferred from the existence of the patent alone. Does RE49302 create biosimilar risk?No. Cariprazine is a chemically synthesized small molecule, not a biologic. The relevant competitors are ANDA-approved generic products, not biosimilars under the Public Health Service Act. The applicable regulatory pathway is section 505(j) of the Federal Food, Drug, and Cosmetic Act. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for strength, dosage form, route and labeling.[4] What manufacturing and intellectual-property barriers remain?The chemical synthesis of cariprazine is separate from the formulation claims in RE49302. A manufacturer may be able to produce the active pharmaceutical ingredient without practicing this patent, but commercial launch requires control of several additional risk areas:
RE49302 does not claim the API manufacturing process. Its commercial leverage is therefore concentrated at the finished-product stage. How does RE49302 compare with a compound patent?
A compound patent usually presents the strongest exclusionary right. RE49302 is narrower but commercially relevant because it targets the final dosage form used in the approved product. What generic launch scenarios exist for cariprazine?Scenario 1: copied formulation and Paragraph IV challengeA generic applicant copies the relevant excipient system, files a Paragraph IV certification and litigates. This creates the highest direct infringement risk under claims 11-15. Scenario 2: non-pregelatinized formulationThe applicant avoids pregelatinized starch and uses a different excipient system. Risk under claims 11-15 declines, but claim 1 remains relevant if mannitol or anhydrous calcium hydrogen phosphate is used and the PK, pH and dissolution limits are met. Scenario 3: section viii carve-outThe applicant removes one or more patented indications from its labeling. This approach may reduce method-of-use exposure but cannot avoid formulation limitations that are practiced for an uncarved indication. Scenario 4: delayed launch after settlementThe applicant accepts a later entry date in exchange for resolution of patent litigation or a license. The commercial effect depends on whether the settlement permits an authorized generic or limits other challengers. Scenario 5: launch after patent expiryThe applicant files a Paragraph III certification or waits for all relevant patent barriers to expire. This provides the lowest litigation risk but sacrifices first-challenger economics. What is the revenue exposure from RE49302?Vraylar is a high-value branded antipsychotic, and generic entry would expose U.S. revenue through price erosion, formulary substitution and volume migration. The exact revenue exposure depends on:
RE49302 is unlikely to determine the entire Vraylar exclusivity period by itself. Its effect is to increase the legal and technical cost of launching a formulation that closely tracks the branded product. Key Takeaways
FAQsCan a cariprazine generic avoid RE49302 by changing the capsule color?No. Capsule color is not a substantive limitation in the supplied claims. The relevant variables are the active ingredient, dose, excipient, treatment method and, for claim 1, PK, dissolution and pH performance. Does claim 11 require the formulation to have a pH between 9.0 and 12.0?No. The express pH limitation appears in claim 1. Claims 11-15 require the specified dose and pregelatinized starch but do not recite the claim 1 pH range. Is a 9 mg cariprazine product covered by claims 11-15?No. Claims 11-15 identify approximately 1.5, 3, 4.5 or 6 mg. A 9 mg formulation may still fall within claim 1 if all of claim 1's limitations are met, including the AUC and Tmax requirements. Can an ANDA applicant omit depression from a cariprazine label?Potentially, if FDA permits a valid section viii carve-out and the remaining label does not induce use covered by the patent. The effect depends on the approved use code and the final labeling. Does RE49302 block manufacture of cariprazine API?No. The supplied claims require administration of a finished solid oral formulation. They do not claim the chemical synthesis or manufacture of cariprazine API. References
More… ↓ |
Drugs Protected by US Patent RE49302
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-001 | Sep 17, 2015 | RX | Yes | Yes | RE49302*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-002 | Sep 17, 2015 | RX | Yes | No | RE49302*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-003 | Sep 17, 2015 | RX | Yes | No | RE49302*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE49302
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2975 | ⤷ Start Trial | |||
| Australia | 2009270823 | ⤷ Start Trial | |||
| Brazil | PI0916241 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
